OBJECTIVE: To evaluate persistence with anti-tumor necrosis factor (TNF) therapy and predictors of discontinuation in patients with rheumatoid arthritis (RA). METHODS: This retrospective analysis used data from RADIUS 1, a 5-year observational registry of patients with RA, to determine time to first- and second-course discontinuation of etanercept, infliximab, and adalimumab. First-course therapy was defined as first exposure to anti-TNF therapy, and second-course therapy was defined as exposure to anti-TNF therapy after the first discontinuation. Kaplan-Meier survival analysis was used to assess persistence, log-rank tests were used to compare therapies, and Cox proportional hazards models were used to assess potential predictors of treatment discontinuation. RESULTS: This analysis included 2418 patients. Mean persistence rates were similar among treatments [first-course: etanercept, 51%; infliximab, 48%; adalimumab, 48% (followup was 54 weeks for etanercept and infliximab and 42 weeks for adalimumab); second-course: 56%, 50%, 46%, respectively (followup was 36 weeks for etanercept and infliximab and 30 weeks for adalimumab)]. Discontinuations of first-course therapy due to ineffectiveness were similar among treatments (etanercept, 19%; infliximab, 19%; adalimumab, 20%) and discontinuations due to adverse events were significantly (p = 0.0006) lower for etanercept than for infliximab (etanercept, 14%; infliximab, 22%; adalimumab, 17%). Predictors from univariable analysis of first- or second-course therapy discontinuation included increased comorbidities (etanercept), female sex (infliximab), Clinical Disease Activity Index > 22 (infliximab), and a Stanford Health Assessment Questionnaire score > 0.5 (adalimumab). CONCLUSION: In this population, first- and second-course persistence was similar among anti-TNF therapies. First-course discontinuation due to adverse events was lower with etanercept compared with infliximab.
OBJECTIVE: To evaluate persistence with anti-tumor necrosis factor (TNF) therapy and predictors of discontinuation in patients with rheumatoid arthritis (RA). METHODS: This retrospective analysis used data from RADIUS 1, a 5-year observational registry of patients with RA, to determine time to first- and second-course discontinuation of etanercept, infliximab, and adalimumab. First-course therapy was defined as first exposure to anti-TNF therapy, and second-course therapy was defined as exposure to anti-TNF therapy after the first discontinuation. Kaplan-Meier survival analysis was used to assess persistence, log-rank tests were used to compare therapies, and Cox proportional hazards models were used to assess potential predictors of treatment discontinuation. RESULTS: This analysis included 2418 patients. Mean persistence rates were similar among treatments [first-course: etanercept, 51%; infliximab, 48%; adalimumab, 48% (followup was 54 weeks for etanercept and infliximab and 42 weeks for adalimumab); second-course: 56%, 50%, 46%, respectively (followup was 36 weeks for etanercept and infliximab and 30 weeks for adalimumab)]. Discontinuations of first-course therapy due to ineffectiveness were similar among treatments (etanercept, 19%; infliximab, 19%; adalimumab, 20%) and discontinuations due to adverse events were significantly (p = 0.0006) lower for etanercept than for infliximab (etanercept, 14%; infliximab, 22%; adalimumab, 17%). Predictors from univariable analysis of first- or second-course therapy discontinuation included increased comorbidities (etanercept), female sex (infliximab), Clinical Disease Activity Index > 22 (infliximab), and a Stanford Health Assessment Questionnaire score > 0.5 (adalimumab). CONCLUSION: In this population, first- and second-course persistence was similar among anti-TNF therapies. First-course discontinuation due to adverse events was lower with etanercept compared with infliximab.
Authors: Jie Zhang; Fenglong Xie; Elizabeth Delzell; Huifeng Yun; James D Lewis; Kevin Haynes; Lang Chen; Timothy Beukelman; Kenneth G Saag; Jeffrey R Curtis Journal: Arthritis Care Res (Hoboken) Date: 2015-05 Impact factor: 4.794
Authors: William J Martin; Man Shim; Harold E Paulus; Sandeep Chaudhari; JingYuan Feng; David Elashoff; Theodore J Hahn; Veena K Ranganath Journal: J Clin Rheumatol Date: 2014-09 Impact factor: 3.517
Authors: Mark T Osterman; Kevin Haynes; Elizabeth Delzell; Jie Zhang; Meenakshi Bewtra; Colleen Brensinger; Lang Chen; Fenlong Xie; Jeffrey R Curtis; James D Lewis Journal: Clin Gastroenterol Hepatol Date: 2013-06-28 Impact factor: 11.382
Authors: Arthur M Mandelin; Philip J Homan; Alexander M Shaffer; Carla M Cuda; Salina T Dominguez; Emily Bacalao; Mary Carns; Monique Hinchcliff; Jungwha Lee; Kathleen Aren; Anjali Thakrar; Anna B Montgomery; S Louis Bridges; Joan M Bathon; John P Atkinson; David A Fox; Eric L Matteson; Christopher D Buckley; Costantino Pitzalis; Deborah Parks; Laura B Hughes; Laura Geraldino-Pardilla; Robert Ike; Kristine Phillips; Kerry Wright; Andrew Filer; Stephen Kelly; Eric M Ruderman; Vince Morgan; Hiam Abdala-Valencia; Alexander V Misharin; G Scott Budinger; Elizabeth T Bartom; Richard M Pope; Harris Perlman; Deborah R Winter Journal: Arthritis Rheumatol Date: 2018-05-03 Impact factor: 10.995
Authors: Vasco C Romão; Maria José Santos; Joaquim Polido-Pereira; Cátia Duarte; Patrícia Nero; Cláudia Miguel; José António Costa; Miguel Bernardes; Fernando M Pimentel-Santos; Filipe Barcelos; Lúcia Costa; José António Melo Gomes; José Alberto Pereira da Silva; Jaime Cunha Branco; José Canas da Silva; José António Pereira da Silva; João Eurico Fonseca; Helena Canhão Journal: Biomed Res Int Date: 2015-04-27 Impact factor: 3.411
Authors: Virginia Martínez-Santana; E González-Sarmiento; Ma Calleja-Hernández; T Sánchez-Sánchez Journal: Patient Prefer Adherence Date: 2013-07-29 Impact factor: 2.711